Assembly Biosciences, Inc. (NasdaqGS: ASMB)
Health Care · Biotechnology · US
$35.42
+0.25% today · +38.3% 1Y
Assembly Biosciences, Inc. (NasdaqGS: ASMB) operates in the Biotechnology industry within the Health Care sector. The company is valued at $721.17M and employs 73 people.
Over the last twelve months the share price has gained 38.3%, trading between 20.23 and 39.71.
Tweenvest scores Assembly Biosciences, Inc. across four factors: quality 37/100, value 58/100. Its strongest factor is value.
ASMB price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $721.17M
- Revenue (TTM)
- $74.84M
- P/E
- —
- EPS
- -0.00
- Dividend yield
- —
- Beta (5Y)
- 1.09
- 52-week high
- $39.71
- 52-week low
- $20.23
- Avg volume (3M)
- —
- Shares outstanding
- 20.36M
- Employees
- 73
- Next earnings
- —
About Assembly Biosciences, Inc.
Assembly Biosciences, Inc. is a biotechnology firm in the clinical development phase, dedicated to identifying and advancing innovative therapeutic solutions for hepatitis B virus (HBV) infections within the United States. Its primary drug candidate, Vebicorvir, has successfully concluded Phase 2 clinical trials for individuals with chronic HBV. The company's development pipeline also features ABI-H3733, which has finished Phase 1a clinical studies, and ABI-4334, currently in pre-clinical assessment for HBV treatment. Assembly Biosciences has forged collaborative partnerships, including agreements with BeiGene, Ltd. and Arbutus Biopharma Corporation, as well as with Antios Therapeutics, Inc., to explore a triple-combination treatment strategy for chronic hepatitis B virus. Additionally, it maintains strategic licensing arrangements with Indiana University Research and Technology Corporation and Door Pharmaceuticals, LLC. Established in 2005, the company was formerly known as Ventrus Biosciences, Inc. before rebranding to Assembly Biosciences, Inc. in June 2014, and its headquarters are located in South San Francisco, California.
- ISIN
- US0453962070
- Founded
- 2005
- Listed since
- Dec 17, 2010
- Exchange
- Nasdaq Global Select
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $464.58B | $262.90 | -1.09% |
| Amgen Inc.NasdaqGS: AMGN | $238.06B | $440.34 | -0.43% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $183.64B | $148.09 | -0.01% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.72B | $547.29 | -1.01% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $81.36B | $814.79 | -2.25% |
| argenx SEENXTBR: ARGX | $65.40B | €897.60 | +2.09% |
| Moderna, Inc.NasdaqGS: MRNA | $59.75B | $149.66 | -5.77% |
| CSL LimitedASX: CSL | $59.19B | AU$172.44 | -0.69% |
Figures last refreshed Aug 18, 2026.